|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
CA2612142A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
ATE516016T1
(de)
*
|
2005-12-05 |
2011-07-15 |
Merck Sharp & Dohme |
Selbstemulgierende formulierungen von cetp- hemmern
|
|
TW200732313A
(en)
*
|
2005-12-15 |
2007-09-01 |
Astrazeneca Ab |
Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
|
|
CA2635087A1
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cholesteryl ester transfer protein inhibitors
|
|
AU2006335108B2
(en)
*
|
2005-12-30 |
2011-04-07 |
Merck Sharp & Dohme Corp. |
CETP inhibitors
|
|
JP5199121B2
(ja)
*
|
2005-12-30 |
2013-05-15 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｅｔｐ阻害剤
|
|
CA2635262C
(en)
|
2005-12-30 |
2011-08-16 |
Merck & Co., Inc. |
1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
|
|
BRPI0707584A2
(pt)
*
|
2006-02-09 |
2011-05-10 |
Merck & Co Inc |
composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
|
|
US8383660B2
(en)
*
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
*
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
CN102317296B
(zh)
|
2007-01-26 |
2015-05-27 |
卡内克制药公司 |
稠合芳烃ptp-1b抑制剂
|
|
US8759383B2
(en)
*
|
2007-03-16 |
2014-06-24 |
Concert Pharmaceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
WO2008137105A1
(en)
|
2007-05-07 |
2008-11-13 |
Merck & Co., Inc. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
WO2008154484A1
(en)
|
2007-06-08 |
2008-12-18 |
Mannkind Corporation |
Ire-1a inhibitors
|
|
EP2170059B1
(en)
*
|
2007-06-20 |
2014-11-19 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
EP2166847B1
(en)
*
|
2007-06-20 |
2014-11-19 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
US8445480B2
(en)
*
|
2007-06-20 |
2013-05-21 |
Merck Sharp & Dohme Corp. |
CETP inhibitors derived from benzoxazole arylamides
|
|
ATE540942T1
(de)
|
2007-07-02 |
2012-01-15 |
Hoffmann La Roche |
Imidazolderivate als ccr2-rezeptor-antagonisten
|
|
CA2697168A1
(en)
*
|
2007-07-26 |
2009-02-05 |
Vitae Pharmaceuticals, Inc. |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
CA2708303A1
(en)
|
2007-12-11 |
2009-06-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
JP5490020B2
(ja)
*
|
2008-01-24 |
2014-05-14 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
|
|
EP2257524B1
(en)
*
|
2008-02-01 |
2016-01-06 |
Brickell Biotech, Inc. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
|
WO2009099901A1
(en)
*
|
2008-02-01 |
2009-08-13 |
Amira Pharmaceuticals, Inc. |
N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
|
|
JP5734666B2
(ja)
*
|
2008-02-11 |
2015-06-17 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
|
|
WO2009102893A2
(en)
|
2008-02-14 |
2009-08-20 |
Amira Pharmaceuticals, Inc. |
CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
|
|
JP5730021B2
(ja)
*
|
2008-02-15 |
2015-06-03 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
|
|
US8497381B2
(en)
*
|
2008-02-25 |
2013-07-30 |
Panmira Pharmaceuticals, Llc |
Antagonists of prostaglandin D2 receptors
|
|
JP5538356B2
(ja)
*
|
2008-03-18 |
2014-07-02 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
|
|
US8426449B2
(en)
|
2008-04-02 |
2013-04-23 |
Panmira Pharmaceuticals, Llc |
Aminoalkylphenyl antagonists of prostaglandin D2 receptors
|
|
US8592410B2
(en)
|
2008-05-01 |
2013-11-26 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
|
|
CA2722427A1
(en)
|
2008-05-01 |
2009-11-05 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
TW201004945A
(en)
|
2008-05-01 |
2010-02-01 |
Vitae Pharmaceuticals Inc |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8063088B2
(en)
*
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
ES2432150T3
(es)
|
2008-07-25 |
2013-12-02 |
Boehringer Ingelheim International Gmbh |
Inhibidores cíclicos de la 11 beta-hidroxiesteroide deshidrogenasa 1
|
|
US8846668B2
(en)
|
2008-07-25 |
2014-09-30 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8487094B2
(en)
|
2008-07-25 |
2013-07-16 |
Boehringer Ingelheim International Gmbh |
Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
EP2348859B1
(en)
*
|
2008-10-01 |
2013-12-04 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone cetp inhibitors
|
|
WO2010039977A2
(en)
|
2008-10-01 |
2010-04-08 |
Amira Pharmaceuticals, Inc. |
Heteroaryl antagonists of prostaglandin d2 receptors
|
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US8383654B2
(en)
|
2008-11-17 |
2013-02-26 |
Panmira Pharmaceuticals, Llc |
Heterocyclic antagonists of prostaglandin D2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
|
AU2010206786A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
|
CA2744946A1
(en)
|
2009-02-04 |
2010-08-12 |
Boehringer Ingelheim International Gmbh |
Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
|
|
US8575166B2
(en)
|
2009-02-05 |
2013-11-05 |
Merck Sharp & Dohme Corp. |
Phthalazine-containing antidiabetic compounds
|
|
MA33216B1
(fr)
|
2009-04-30 |
2012-04-02 |
Boehringer Ingelheim Int |
Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
|
|
EP2440537A1
(en)
|
2009-06-11 |
2012-04-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
|
|
JP5749263B2
(ja)
|
2009-07-01 |
2015-07-15 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
|
|
CN102596902A
(zh)
|
2009-08-05 |
2012-07-18 |
潘米拉制药公司 |
Dp2拮抗剂及其用途
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
EP2496589B1
(en)
|
2009-11-05 |
2014-03-05 |
Boehringer Ingelheim International GmbH |
Novel chiral phosphorus ligands
|
|
WO2011088025A1
(en)
|
2010-01-15 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2012046681A1
(ja)
|
2010-10-04 |
2012-04-12 |
興和株式会社 |
脂質代謝関連ｍＲＮＡの発現抑制剤
|
|
JP2013531636A
(ja)
|
2010-05-26 |
2013-08-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
EP2582698B1
(en)
|
2010-06-16 |
2016-09-14 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
EP2585444B1
(en)
|
2010-06-25 |
2014-10-22 |
Boehringer Ingelheim International GmbH |
Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
|
|
WO2012058187A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted oxazolidinone cetp inhibitor
|
|
KR20130137628A
(ko)
|
2010-11-02 |
2013-12-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
대사 장애를 치료하기 위한 약제학적 병용물
|
|
EP2468736A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468735A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
WO2012101142A1
(en)
|
2011-01-26 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for assessing a subject's risk of having a cardiovascular disease.
|
|
BR122021002201A8
(pt)
|
2011-02-25 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
|
|
HRP20170422T1
(hr)
*
|
2011-04-12 |
2017-06-16 |
Chong Kun Dang Pharmaceutical Corp. |
3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
|
|
EP2730281B1
(en)
*
|
2011-07-07 |
2018-11-28 |
Mochida Pharmaceutical Co., Ltd. |
Anti-obesity agent comprising high-purity epa
|
|
CN103648495A
(zh)
|
2011-07-08 |
2014-03-19 |
诺华股份有限公司 |
在高甘油三酯对象中治疗动脉粥样硬化的方法
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
EP2773210A4
(en)
*
|
2011-10-31 |
2015-07-22 |
Merck Sharp & Dohme |
Process for a cetp inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
EP2789347A4
(en)
|
2011-11-29 |
2015-12-16 |
Kowa Co |
MEANS TO INHIBIT THE EXPRESSION OF NPC1L1 AND / OR LIPG-MRNA AND MEDICAMENTS FOR THE PREVENTION AND / OR TREATMENT OF ADIPOSITAS
|
|
MX352611B
(es)
*
|
2011-11-30 |
2017-11-29 |
Dae Woong Pharma |
Composicion farmaceutica para evitar o tratar hipertrigliceridemia o enfermedades asociadas con hipertrigliceridemia.
|
|
WO2013091696A1
(en)
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
US9353101B2
(en)
|
2012-05-02 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic CETP inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
CN103958484B
(zh)
*
|
2012-07-19 |
2015-11-25 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
US9382243B2
(en)
|
2012-08-22 |
2016-07-05 |
Merck Sharp & Dohme Corp. |
Azabenzimidazole tetrahydropyran derivatives
|
|
WO2014099836A1
(en)
|
2012-12-19 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
|
WO2014099834A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
EP2943474B1
(en)
|
2013-01-31 |
2017-07-05 |
Chong Kun Dang Pharmaceutical Corp. |
Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
EP3027619B1
(en)
|
2013-07-30 |
2019-01-02 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors
|
|
US9688630B2
(en)
|
2013-10-10 |
2017-06-27 |
Merck Sharp & Dohme Corp. |
3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
CN105814064A
(zh)
|
2013-12-17 |
2016-07-27 |
默沙东公司 |
作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
|
|
WO2015106674A1
(zh)
*
|
2014-01-14 |
2015-07-23 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
US10011572B2
(en)
|
2014-07-29 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
ES2825675T3
(es)
|
2014-07-30 |
2021-05-17 |
Hoffmann La Roche |
Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
CN109415355A
(zh)
|
2016-06-29 |
2019-03-01 |
奥赖恩公司 |
苯并二噁烷衍生物及其药物用途
|
|
KR101902002B1
(ko)
*
|
2016-07-19 |
2018-09-27 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
CN109563019A
(zh)
*
|
2016-08-17 |
2019-04-02 |
诺华股份有限公司 |
Nep抑制剂合成的新方法和中间体
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
CN112888432A
(zh)
|
2018-08-09 |
2021-06-01 |
英国达科(莱得海德)制药有限公司-楚歌分公司 |
用于延迟新发作2型糖尿病的发生和用于减慢2型糖尿病的进展和治疗2型糖尿病的方法
|
|
AU2020232350A1
(en)
|
2019-03-07 |
2021-07-29 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
Methods for treating or preventing heart failure and reducing risk of heart failure
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
CN119684381A
(zh)
|
2019-07-19 |
2025-03-25 |
生物合成股份公司 |
烟酰胺呋喃核糖苷盐的结晶形式以及包含其的营养补充剂和药物组合物
|
|
CA3179702A1
(en)
|
2020-05-05 |
2021-11-11 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|
|
CA3179700A1
(en)
|
2020-05-05 |
2021-11-11 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|
|
KR102651062B1
(ko)
*
|
2020-10-08 |
2024-03-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
US20240360103A1
(en)
*
|
2021-06-30 |
2024-10-31 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
IL311444A
(en)
|
2021-10-01 |
2024-05-01 |
Nuvalent Inc |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|